The MLR review cycle, step by step, and where it typically stalls
How a promotional asset actually moves through Medical, Legal, and Regulatory review, and the points where it usually gets stuck.
MLR review has a name that makes it sound like one step. It's really three separate functions, each with its own reviewer, its own concerns, and its own ability to send an asset back to the start.
What it is
Medical reviews scientific and clinical accuracy: does the asset represent the data correctly, and does any implied claim hold up against the evidence. Legal reviews claims and liability exposure: is the asset making a promise the company can defend, and does it expose the brand to risk beyond the regulatory question. Regulatory reviews the asset against the applicable advertising and labeling rules: does it stay on-label, does it carry adequate fair balance, is the ISI where it needs to be.
In a traditional workflow, an asset moves through these three functions in sequence, not in parallel. Medical reviews first, then Legal, then Regulatory, with each function often working from the version the previous one just signed off on.
Why it matters
The sequential structure is the part that actually slows a review cycle down, more than the individual reviews themselves. If Regulatory catches an issue after Medical and Legal have already approved, the asset doesn't just get a Regulatory fix. It often has to go back through Medical and Legal again, because the fix itself (a reworded claim, a shortened benefit statement) is a change those functions haven't seen yet.
That's why a single flagged issue late in the cycle can cost multiple review rounds instead of one. The fix is small; the reset is not.
How it actually works
A cycle usually looks something like this:
- Intake: a near-final asset (copy, layout, and any required legal disclosures already drafted) enters the queue.
- Medical review: claims are checked against clinical evidence and the approved label.
- Legal review: claims and any comparative or liability-sensitive language are checked against company risk tolerance.
- Regulatory review: the asset is checked against fair balance, ISI placement, and label-consistency rules.
- Reconciliation: if any function requests a change, the asset is revised and, depending on how substantive the change is, sent back through some or all of the earlier steps.
- Sign-off: once all three functions approve the same version, the asset is cleared to ship.
The stall almost always happens at step 5. A change requested at Regulatory review that touches a claim Medical already checked doesn't just need a Regulatory re-check, it typically needs to go back to Medical too, since the wording changed.
Common misunderstandings
A common assumption is that a faster individual reviewer, or a faster review tool, is what shortens the cycle. In practice the biggest time cost is the number of full round trips an asset makes, not how long any single review takes. An asset that enters review already claim-linked, fair-balanced, and ISI-compliant tends to need far fewer round trips, because there's less for any one function to flag in the first place.